Guelph, Ontario, CA—Nutrasource Pharmaceutical and Nutraceutical Services has announced the approval of an amendment to its Controlled Drugs & Substances Dealer’s License issued by Health Canada earlier this year.

The license was expanded to include several controlled psychedelic, psychostimulant, and pain management drugs, including:
  • Psilocybin
  • Psilocin
  • Ketamine
  • LSD
  • Methamphetamines
  • Synthetic Cannabinoids
  • Opioids
  • DMT
“This initiative is a natural progression building and diversifying our portfolio of licenses including our Institution-Wide Cannabis Research License and Cage Level Security License,” said Joshua Baisley, Vice President, Clinical Design and Delivery, in the press release. “We are pleased to continue supporting our current and future clients in the areas of pharmaceutical development with botanical agents, psychedelics, and opioid alternatives.”

Related: Product Profiles: Nutrasource IGEN Testing Program Nutrasource Joins National Animal Supplement Council as Preferred Supplier BIPOC May Experience Relief from Effects of Racism Through Psychedelics

The new approval will give Nutrasource’s clients an opportunity to conduct early-stage clinical studies, including Bioavailability/Bioequivalence and proof-of-concept studies, on many novel controlled substances in Canada.

The approval comes as interest is increasing in opioid alternatives, as well as other agents related to the central nervous system and neurology, for uses in disorders including anxiety, depression, and Alzheimer’s, as well as for use in pain management.

“Working with Sponsors in the Natural Health Product industry, we often see a transition into the pharmaceutical space as an avenue for innovation,” said Tania John, Vice President, NHP & Pharmaceutical Regulatory Sciences. “Obtaining this license further fulfills Nutrasource’s mission of helping health companies launch scientifically substantiated products and aligns with our expanded pharmaceutical regulatory services. Ultimately, this higher level of security allows us to better serve our clinical and regulatory clients, including those interested or already in the controlled drugs and substances sector.”